Target Inhibitor Working Group
Weijia studies the potential therapeutic targets against NRAS mutant melanoma.
Manoela Tiago, PhD
Targeting drug-tolerant tumor cells to targeted therapy in cutaneous melanoma
Mai studies the stress responses in NRAs mutant melanoma.
Claudia Capparelli, PhD
Claudia studies SOX10 and GrbB3 regulation and tumor heterogeneity.
Uveal Melanoma Working Group
Vivian Chua, PhD
Vivian studies the role of stromal growth factors in regulating uveal melanoma response to targeted inhibitors and is currently studying dependencies that could be therapeutically targetable in BAP1-deficient uveal melanoma.
Timothy Purwin, MS
Clinical Informatics Specialist
Computational Biology, bioinformatics and loss of BAP1 in a Pan-Cancer setting.
Anna Han, PhD
Anna studies the therapeutic options that target metabolism in uveal melanoma and in subtypes of BAP1-deficient uveal melanoma.
Usman studies the role BAP1 mutations play in altering signaling pathways to promote metastatic potential in uveal melanoma.
Immuno-oncology Working Group
Nicole Wilski, PhD
Nicole studies the effects of BRAF and MEK inhibitors on promoting necroptosis in cancer cells through gasdermin E (GSDME) cleavage and determining the ways in which GSDME modulation can alter the tumor immune microenvironment.
Megane Vernon, PhD
Megane studies the Impact of the tumor immune microenvironment on residual cells in response to BRAF and MEK inhibitor in cutaneous.
Sheera studies lineage transcription factor regulation of the anti-tumor immune response.
Danielle is studying the regulation of Gasdermin-E.